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ABSTRACT 
Objective: Patients with a family history of cancer may be genetically predisposed to 
carcinogenesis. This could affect risk of recurrence, second primary tumors and overall 
outcomes after treatment of a primary cancer. We evaluated the association between 
family history of cancer and disease-specific survival in a cohort of patients with primary 
head and neck squamous carcinoma. 
Study Design: 643 incident head and neck squamous carcinoma patients recruited 
through the University of Michigan Specialized Program of Research Excellence were 
followed for up to 5 years for survival. Participants were interviewed about personal and 
family cancer history, demographic information and behavioral habits. 
Methods: Cox proportional hazards models were used to estimate the association 
between family history of cancer in a first degree relative and disease-specific survival. 
Results: After multivariable adjustment, we found a non-significant inverse association 
between family history and HNSCC mortality (HR=0.88, 95%CI 0.57-1.35). This 
association was stronger and statistically significant among patients who currently both 
drank alcohol and smoked cigarettes at diagnosis (HR=0.46, 95% CI=0.22 – 0.97); no 
association was observed among participants who did not both drink and smoke at the 
time of diagnosis (HR=1.14, 95% CI=0.68–1.91; p-interaction=0.046). 
Conclusion: Results from this study suggest that having a family history of cancer may 
be associated with improved disease-specific survival in patients who use tobacco and 
alcohol. Additional large studies, particularly in populations including non-whites and 
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women, are needed to confirm or refute the association and to elucidate the genetic 
factors that may underlie this potential association. 
 
Keywords: head and neck cancer, survival, family history, mortality, epidemiology 
Level of Evidence: 2b 
Abbreviations: HNC-Head and Neck Cancer, ACE- Adult Comorbidity Evaluation, 
SPORE- Specialized Program of Research Excellence 
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INTRODUCTION 
Family history is one of the most widely accepted risk factors for development of 
cancer. For most cancer sites, individuals with a family history of cancer tend to have a 
2-3 times greater risk of developing cancer than those without a family history.1 Several 
studies have examined the relationship between family history of cancer and risk of 
developing a head and neck squamous carcinoma (HNSCC). One large pooled analysis 
found that individuals with a family history of HNSCC were almost twice as likely to 
develop the disease as those with no family history of HNSCC, but that there was little 
association between family history of other types of cancer and risk of developing 
HNSCC.2 Despite this strong evidence for a relationship between family history and 
HNSCC incidence, there remains little evidence for an association between family 
history and survival among patients diagnosed with HNSCC.  
Survival after diagnosis with HNSCC varies depending on many factors including 
a patient’s behaviors, health status, tumor characteristics, and treatment; it is well-
established that HPV infection and lower stage at diagnosis have been associated with 
better HNSCC survival, while tobacco and alcohol use have been associated with 
poorer outcomes.3 This may change somewhat in the future as new staging guidelines 
which consider HPV status when staging HNSCC patients become widely used.4 
Patients with an index HNSCC have a well-known high incidence of second primary 
tumors approaching 4% per year of follow up that could have a negative influence on 
overall survival.5 Other factors have been examined in relation to survival with less 
consensus about their association.6 One study found that patients with a pessimistic 
outlook about their cancer had decreased survival compared to optimistic patients who 
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were living in a supportive household.7 Health insurance status also predicted survival in 
HNSCC patients; patients who were insured through Medicaid or those who were 
uninsured had poorer survival than those with other  insurance.8 However, to our 
knowledge, no studies have examined the association between a family or personal 
history of cancer and HNSCC-specific survival. 
 
In the present analysis, we address this gap in the literature by examining the 
association between family history of cancer and HNSCC-specific survival in a large 
cohort HNSCC patients recruited through the University of Michigan Head and Neck 
Cancer Specialized Program of Research Excellence (SPORE). 
 
MATERIALS AND METHODS 
Study Population 
This analysis included 687 participants with incident head and neck cancer 
recruited through the University of Michigan Head and Neck Cancer SPORE Program. 
Participants were included if they were diagnosed with previously untreated squamous 
cell carcinoma of the head and neck from 2008-2013. Patients were recruited from two 
main clinics that cared for HNSCC patients within the University of Michigan Health 
System with the approval of the University of Michigan IRB. Participants were not 
recruited if they had been previously treated for their current HNC, if their HNC was not 
a primary site but a metastasis from another site, or if they were experiencing recurrent 
disease from a primary HNSCC diagnosed fewer than five years ago. After excluding 
participants with missing information about family history of cancer, 643 participants 
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were included in the analytic cohort. Sites of HNSCC among the study population were 
larynx (19.8%), oropharynx (39.0%), oral cavity (37.8%) and hypopharynx (3.4%). There 
were 473 males and 170 females, ranging in age from 25-95 years old at diagnosis.  
 
Exposure, outcome, and covariate assessment 
After diagnosis, each participant was approached by a trained interviewer and 
completed an initial evaluation. This evaluation collected information about their 
personal and family history of cancer, demographic information, and behavioral habits. 
Participants were followed for the next five years; updated exposures were assessed 
through yearly self-administered surveys that evaluated each participant’s physical and 
emotional well-being, behavioral habits and overall health. 
As described above, the main exposure, family history of cancer, was 
ascertained through the initial evaluation that patients completed at recruitment. 
Participants were asked if any of their family members had ever been diagnosed with 
cancer. If the patient responded “yes”, the interviewer inquired about the family 
member’s relationship to the patient and what type of cancer they experienced.  The 
interviewer asked the patient if the cancer spread to other sites and if so, where was the 
first diagnosis to ensure that the patient reported the primary cancer location.  
Participants were categorized as having had a family history of cancer if they reported a 
first degree relative (i.e. a parent, sibling, or child) having had any cancer other than 
non-melanoma skin cancer. Otherwise, they were classified as not having had a family 
history of cancer. Sensitivity analyses were conducted examining family history in a 
parent and family history in a sibling separately. 
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Overall survival was determined through clinical patient follow up, medical 
records of treating or referring physicians, annual surveys or personal communication 
with family members. Linkage with the Social Security Death Master File (SSDMF) was 
conducted annually to ascertain participant survival if patients were lost to follow up. If a 
participant was in the SSDMF, did not respond to the mailed survey, or if a family 
member informed us that they had died, medical records were reviewed by trained 
study personnel to determine the date of death and whether the death was due to 
HNSCC or another cause. Follow-up time was calculated from the date of diagnosis to 
date of death from HNSCC, death from another cause, or the censoring date (2/1/2014), 
whichever was earliest. The median survival time was 24.4 months. Cases were defined 
as death from HNSCC as the underlying cause (n=95); patients with all other causes of 
death were censored at their death date. 
 
Statistical Analysis 
Cox proportional hazards models were used to estimate the hazard ratio (HR) 
and 95% confidence interval (CI) of death from HNSCC according to family history of 
cancer (yes/no). The following factors known or hypothesized to be associated with risk 
of HNSCC or to influence cancer survival were included as potential confounders. Age 
at diagnosis, tobacco and alcohol use were gathered from the initial evaluation at 
baseline. HPV status was assessed by PCR technique for patients whose tumor tissue 
was available and was assigned positive, negative or missing for each participant based 
on test results. Comorbidities were measured by utilizing Adult Comorbidity Evaluation 
scale, a validated medical record-based comorbidity instrument, and each participant 
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was assigned a score (0=No comorbidities, 1=Mild, 2=Moderate, 3=Severe) based on 
comorbidities recorded in the patient’s medical record.9 In addition, tumor-specific 
factors known to be associated with survival such as primary tumor site and tumor stage 
of each individual’s cancer were also included in the model. Thus, our final multivariable 
model included the following variables: smoking status (current, former, never), drinking 
status (current, former, never), ACE score (none, mild or moderate/severe), stage (1, 2, 
3, or 4), site (larynx, oral cavity, oropharynx, or hypopharynx), personal history of HNC 
(yes or no), and HPV status (negative, positive or missing). The association between 
family history and the hazard of death from HNSCC was also estimated for the following 
subsets of patients: age at diagnosis ≤ 50 vs >50 years, current drinkers and smokers 
vs. all others, HPV positive vs. negative, and disease site of hypopharynx and larynx vs. 
oral cavity and oropharynx. Statistical interaction was assessed using the likelihood 
ratio test. All analyses were conducted using SAS version 9.4. 
 
RESULTS 
Characteristics of the participants by family history of cancer are shown in Table 
1. Participants with a family history of cancer were more likely to be former (35.5%) or 
never (24.5%) smokers and participants without a family history were more likely to 
currently smoke (46.8%). Participants with a family history were more likely to be former 
drinkers compared to current drinkers, but the proportion of never drinkers in both 
groups was the same. The distribution of primary tumor sites of head and neck cancer 
were similar between groups but among participants with a family history of cancer the 
most common site was oropharynx, whereas among participants without a family history 
Page 8 of 18
John Wiley & Sons
The Laryngoscope
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
9 
 
of cancer, the most common site was oral cavity. The stage distribution at diagnosis 
with HNSCC differed by family history of cancer; patients with a family history of cancer 
were slightly more likely to be diagnosed at stage 1, whereas those without a family 
history were slightly more likely to be diagnosed at stage 4. Patients with a family 
history of cancer were more likely to have a personal history of cancer and were more 
likely to have moderate comorbidities compared to the group of patients without a family 
history of cancer (Table 1). 
After adjustment for age at diagnosis, we observed a non-significant inverse 
association between family history of cancer and death in HNSCC patients (HR=0.83, 
95% CI=0.55 - 1.26, p=0.38). Further adjustment for several potential confounding 
variables did not meaningfully change the association (HR=0.88, 95%CI 0.57-1.35, 
p=0.56) (Table 2). There was no difference in the association when we looked at family 
history in a parent or a sibling separately (data not shown).  We were unable to examine 
family history of HNSCC separately; only 22 participants had a family history of HNSCC 
and only 3 of them died of HNSCC during follow-up. 
We observed an interaction with tobacco and alcohol use such that among 
participants who currently both drank alcohol and smoked cigarettes at the time of 
diagnosis, a family history of cancer was associated with better survival (HR=0.46, 95% 
CI=0.22 – 0.97); no association was observed between family history of cancer and HNC 
survival among participants who did not both drink and smoke at the time of diagnosis 
(HR=1.14, 95% CI=0.68 – 1.91; p for interaction = 0.046; Table 3).  There was an 
inverse association between family history and mortality in participants without HPV 
infection and in those whose cancer was in the hypopharynx or larynx, but these 
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interactions were not statistically significant (Table 3). There was no interaction by age 
at diagnosis (Table 3). Further adjustment for stage in any subgroup did not 
meaningfully alter the findings (data not shown).  
DISCUSSION 
In this study of HNSCC patients, although a family history of cancer was not 
significantly associated with survival overall, it was associated with improved survival in 
HNSCC patients who were currently drinking and smoking at the time of diagnosis. A 
large, pooled analysis of family history and HNC incidence found increased risk of 
developing HNC in the same subgroups, providing coherent evidence that family history 
may be related to HNC due to tobacco and alcohol exposure.2 To our knowledge, this is 
the first study to examine family history of cancer in relation to survival among HNC 
patients. However, this relationship has been studied in other cancers. 
Several studies have investigated how a family history of colorectal cancer is 
related to survival among colorectal cancer patients. A study by Lee et al. found that 
patients with stage 3 colon cancer who had a family history had better overall and 
disease free survival than patients without a family history of colorectal cancer.10 In 
another study of patients with colorectal cancer; Morris et al. found similar results. 
Patients who had a family history of colon cancer had better survival than those without 
a family history of colon cancer and they also observed that patients who had more than 
one relative with a history of colon cancer had even better survival than those without a 
family history of cancer.11 Similar results have been reported about the relationship with 
survival among breast cancer patients who have a family history of breast cancer. A 
study by Malone et al. reported that, among women under the age of 45 with invasive 
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breast cancer, those who had a family history had better survival.12 Russo et al. 
reported that breast cancer cases with a first degree relative with a history of breast 
cancer had a non-statistically significant better survival than cases without a family 
history .13 It should be noted that the family history-survival association may differ for 
patients with an inherited familial cancer syndrome.  
Fewer studies have examined family history of any cancer in relation to survival 
among patients with cancer at a particular site. A study by Isla et al. investigated the 
relationship between family history of any cancer and overall survival of women with 
lung cancer. Lung cancer patients who had a family history of any type of cancer had 
significantly longer survival than those without a family history of cancer; median overall 
survival was 23.0 months for lung cancer patients without a family history of cancer and 
median overall survival for lung cancer patients with a family history of various types of 
cancer was 25.3 months.14 They also determined that participants with a family history 
of cancer had a significantly higher proportion of current smokers compared to those 
who did not have a family history of cancer.14These findings are similar to those 
reported in the current analysis.  
It is difficult to pinpoint the exact reason why having a family history of cancer 
may improve survival. That it has been observed across different cancer types with the 
exception of inherited cancer syndromes suggests that the finding may not be due to 
chance. One frequently suggested explanation for the findings for colorectal and breast 
cancer is lead-time bias: i.e. individuals with a family history may undergo more 
aggressive screening, and ultimately become diagnosed at an earlier stage which would 
lead to improved survival.13 Because screening for HNC is not common, the protective 
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association we observed cannot be explained by screening. In addition, adjustment for 
stage at diagnosis did not alter our results for family history in any subgroup, suggesting 
that lead-time bias does not explain our findings.  It is possible that delay in diagnosis 
and treatment, regardless of tumor stage could influence survival outcomes15 with 
potentially less delay in patients with a family history, however we did not have such 
data for this cohort.  
To our knowledge, this is the first analysis assessing the relationship between 
family history of cancer and survival among HNSCC cases. Our study has many 
strengths including a large sample size representing various sites of HNSCC, excellent 
survival ascertainment, and information on many clinical tumor characteristics, potential 
confounders, and effect modifiers. One potential limitation of our study is that family 
history of cancer was self-reported.  It is unlikely that any misclassification of family 
history would be different in those patients who survived compared to those that did not; 
thus any misclassification would be non-differential and would bias our findings toward 
the null. Thus, the true protective association between family history and HNC survival 
among those exposed to tobacco and alcohol might actually be stronger than what we 
observed. Our study population consisted mainly of white men, so these results may not 
be generalizable to other races or to women.  Finally, although the differences in 
demographics in this retrospective analysis were not significant, there was a tendency 
for patients with a family history to have a lower percentage of severe co-morbidities 
and higher frequency of oropharyngeal cancers and Stage I tumors which, despite our 
adjustment for them as potential confounding factors, could influence outcomes.  
CONCLUSIONS 
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Results from this study suggest that having a family history of cancer may be 
associated with improved disease-specific survival in HNSCC patients who use tobacco 
and alcohol. Additional large studies, particularly in populations including non-whites 
and women, are needed to confirm or refute the suggested association and to elucidate 
potential genetic factors that may underlie this association before recommendations can 
be translated in the clinical setting. 
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Table 1. Selected baseline characteristics [means (standard deviation) or number (percent)] of SPORE 
patients by family history of cancer 
 Family History  
 Yes No p-value 
N 374 269  
Age at Diagnosis (years) 62.7± 11.4 59.0±12.2 0.0001 
Sex    
Male 276 (73.8%) 197 (73.2%) 0.87 
Race    
White 357 (95.5%) 253 (94.1%) 0.43 
BMI (kg/m
2
) 27.0±6.1 27.2±6.1 0.64 
Smoking  Status    
Current 150 (40.1%) 126 (46.8%) 0.23 
Former 132 (35.3%) 82 (30.5%)  
Never 92 (24.6%) 61 (22.7%)  
Drinking Status    
Current 237 (63.4%) 187 (69.5%) 0.20 
Former 102 (27.3%) 57 (21.2%)  
Never 35 (9.3%) 25 (9.3%)  
Disease site    
Larynx 78 (20.9%) 49 (18.2%) 0.47 
Oral Cavity 137 (36.6%) 114 (42.4%)  
Oropharynx 147 (39.3%) 96 (35.7%)  
Hypopharynx 12 (3.2%) 10 (3.7%)  
Stage at diagnosis    
1 67 (17.9%) 36 (13.4%) 0.45 
2 43 (11.5%) 30 (11.2%)  
3 53 (14.2%) 38 (14.1%)  
4 211 (56.4%) 165 (61.3%)  
Treatment    
Surgery alone 98 (26.2%) 59 (21.9%) 0.42 
Surgery + adjuvant 70 (18.7%) 61 (22.7%)  
Radiation (+/- adjuvant surgery) 26 (7.0%) 18 (6.7%)  
Chemoradiation (+/- adjuvant surgery) 155 (41.4%) 106 (39.4%)  
Chemotherapy alone or  
palliative therapy 
 
25 (6.7%) 
 
25 (9.3%) 
 
HPV Status    
Positive 80 (38.7%) 54 (38.8%) 0.87 
Personal History of Cancer    
Yes 98 (26.2%) 42 (15.6%) 0.001 
Ace Score    
None 92 (24.6%) 77 (28.6%) 0.02 
Mild 168 (44.9%) 136 (50.6%)  
Moderate/Severe 114 (30.5%) 56 (20.8%)  
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Table 2. Association between family history of cancer and HNC mortality among patients in the 
University of Michigan Head and Neck Cancer SPORE 
  
# HNC Deaths Person-Years HR (95% CI)
*
 HR (95% CI)
†
 
Family History No 42  606.33 1.0 (ref) 1.0 (ref) 
 Yes 53  844.16 0.83 (0.55,1.26) 0.88 (0.57, 1.35) 
* - Adjusted for Age at Diagnosis 
† - Adjusted for Age at Diagnosis, Personal History of Cancer, Personal History of HNC, Disease Site, Stage, 
ACE Score, Smoking Status, Drinking Status, and HPV Status 
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Table 3 -  Association
*
 between family history of cancer and HNC mortality among patients in the University of Michigan 
Head and Neck Cancer SPORE, stratified by selected potential effect modifiers 
 
  
No Family History Yes Family History 
 
  # HNC  
Deaths 
HR (95% CI) 
# HNC  
Deaths 
HR (95% CI) p for interaction 
Age at Diagnosis ≤ 50 12 1.0 (ref) 30 1.18 (0.48 - 2.86)  
 > 50 9 1.0 (ref) 44 0.88 (0.54 - 1.44) 0.58 
Current Drinker 
and Smoker 
No 22 1.0 (ref) 42 1.14 (0.68 – 1.91)  
 Yes 20 1.0 (ref) 11 0.46 (0.22 – 0.97) 0.046 
HPV status Negative 22 1.0 (ref) 25 0.60 (0.33 – 1.08)  
 positive 5 1.0 (ref) 7 0.96 (0.30 – 3.03) 0.47 
Disease Site Oral Cavity or 
Oropharynx 
29 1.0 (ref) 39 0.96 (0.59 – 1.55)  
 Hypopharynx 
or Larynx 
13 1.0 (ref) 14 0.55 (0.26 – 1.18) 0.23 
* - Adjusted for Age at Diagnosis 
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